ArticleAmerican journal of cancer research2026
Diagnostic efficacy of the TSPOT assay for tuberculosis infection and drug resistance in mycobacterium tuberculosis in patients with malignant tumors.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppression in cancer patients clearly elevates the risk of acquiring tuberculosis (TB) infection, and traditional diagnostic methods are characterized by low sensitivity (Sen) and long turnaround times. Although the interferon-gamma release assay (IGRA) is widely used, its ability to distinguish active tuberculosis (ATB) from latent tuberculosis infection (LTBI) in cancer patients, as well as its relationship with drug resistance (DR), remains unclear. This study aimed to evaluate the diagnostic efficacy of T-SPOT for active tuberculosis and its ability to distinguish active tuberculosis from latent tuberculosis infection in patients with malignant tumors. A retrospective analysis was conducted on data from 634 patients with malignant tumors, and patients were grouped: active tuberculosis (ATB) group (AG, n = 76), LTBI group (BG, n = 184), and non-TB group (CG, n = 374). The interferon-gamma (IFN-γ) response induced by Early Secreted Antigenic Target 6 (ESAT-6)/Culture Filtrate Protein 10 (CFP-10) was detected by TSPOT, and the relationship between TSPOT and DR was analyzed. Subgroup analysis and multivariate regression were used to explore the immune-related factors affecting the positive rate of TSPOT. The results showed Sen for ATB was 86.8%, and specificity (Spe) was 73.3%. The Sen for screening TB infections was 80.4%, with a Spe of 98.4% and a positive predictive value (PPV) of 97.2%. The Spe for differentiating ATB from LTBI was only 22.3%. The overall DR rate in the AG was 59.2% (45/76), including rifampicin (RIF) resistance (36.8%), multidrug-resistant TB (MDR-TB) (21.1%), and pre-extensively drug-resistant TB (Pre-XDR-TB) (7.9%). The median total spot count of TSPOT in the drug-resistant group was significantly lower than that in the drug-sensitive group [52 (IQR 25-85) vs. 120 (IQR 85-188),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.